Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cumulative dose

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44349   clinical trials with a EudraCT protocol, of which   7376   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    780 result(s) found for: Cumulative dose. Displaying page 6 of 39.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    EudraCT Number: 2010-023409-37 Sponsor Protocol Number: AMLSG_15-10 Start Date*: 2011-03-02
    Sponsor Name:University Hospital Ulm
    Full Title: Randomized Phase III Study of Low-Dose Cytarabine and Etoposide with or without All-Trans Retinoic Acid in Older Patients not Eligible for Intensive Chemotherapy with Acute Myeloid Leukemia and NPM...
    Medical condition: Adult patients (>60) with AML and NPM1 mutation ineligible for intensive chemotherapy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2004-001126-24 Sponsor Protocol Number: AGO/GAS/04/01 Start Date*: 2004-10-25
    Sponsor Name:University Hospital Ghent
    Full Title: Feasibility of radiotherapy and concomitant gemcitabine and oxaliplatin in locally advanced pancreatic cancer and distal cholangiocarcinoma
    Medical condition: Pancreatic cancer or distal cholangiocarcinoma
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2004-000145-38 Sponsor Protocol Number: C0743T06 Start Date*: 2004-11-16
    Sponsor Name:Centocor B.V.
    Full Title: A Phase 2, Double-blind, Placebo-controlled, Randomized, Dose-ranging Study of Multiple Subcutaneous Injections of Human Monoclonal Antibody to IL-12p40 (CNTO 1275) in Subjects with Relapsing-remit...
    Medical condition: Relapse-remitting Multiple Sclerosis (RRMS)
    Disease: Version SOC Term Classification Code Term Level
    10048393
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-005208-26 Sponsor Protocol Number: P13/12 Start Date*: 2016-02-22
    Sponsor Name:Centre Hospitalier de Versailles
    Full Title: CANDIDATE THERAPIES IN COMBINATION OR SEQUENTIALLY WITH TYROSINE KINASE INHIBITORS IN CHRONIC PHASE CHRONIC MYELOGENOUS LEUKAEMIA (CP-CML) PATIENTS IN COMPLETE CYTOGENETIC RESPONSE WITHOUT ACHIEVIN...
    Medical condition: CHRONIC PHASE CHRONIC MYELOGENOUS LEUKAEMIA (CP-CML)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10058246 Chronic myelogenous leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-002388-33 Sponsor Protocol Number: ZKSJ0086 Start Date*: 2016-09-05
    Sponsor Name:Friedrich-Schiller-University Jena
    Full Title: Therapeutic drug monitoring (TDM) for personalized antibiotic treatment with piperacillin-tazobactam (PipTaz) in patients with febrile neutropenia after myelo-suppressive cytostatic chemotherapy
    Medical condition: Patients with febrile neutropenia after myelo-suppressive chemotherapy treated with piperacillin/tazobactam
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-004867-19 Sponsor Protocol Number: v1330032015 Start Date*: 2015-02-24
    Sponsor Name:Clinic for General Anesthesiology, Intensive Care and Pain Management
    Full Title: Perioperative fluid management in patients receiving major abdominal surgery – Effects of normal saline versus an acetate buffered balanced infusion solution on the necessity of catecholamines for ...
    Medical condition: hemodynamic stability of patients undergoing major surgery
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-000535-18 Sponsor Protocol Number: ML17632 Start Date*: 2005-05-18
    Sponsor Name:Roche Pharma (Schweiz) AG
    Full Title: Prospective, multicenter study to evaluate the renal safety of 6 mg ibandronic acid infusions over 15 min or 60 min in patients with metastatic bone disease due to breast cancer.
    Medical condition: The target population for this trial are female patients with primary breast cancer with metastatic bone disease.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-002320-25 Sponsor Protocol Number: UC_0106/1712 Start Date*: 2018-07-03
    Sponsor Name:UNICANCER
    Full Title: Effectiveness assessment of riluzole in the prevention of oxaliplatin-induced peripheral neuropathy: A phase II randomized study by the UNICANCER with cooperation of AFSOS.
    Medical condition: Colorectal cancer stage II/III with adjuvant oxaliplatin-based chemotherapy (simplified FOLFOX4)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-004456-42 Sponsor Protocol Number: P2021/Anesth/MIDEXMRI Start Date*: 2022-06-21
    Sponsor Name:Hôpital Universitaire Des Enfants Reine Fabiola
    Full Title: Prospective, randomized, double-blind, double-dummy, active-controlled, phase 3 clinical trial comparing the safety and efficacy of intranasal dexmedetomidine to oral midazolam as premedication for...
    Medical condition: pre-school pediatric population undergoing magnetic resonance imaging
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-002655-14 Sponsor Protocol Number: 29BRC18.0144 Start Date*: 2019-09-05
    Sponsor Name:CHRU BREST
    Full Title: BAriCitinib Healing Effect in earLy pOlymyalgia Rheumatica (BACHELOR study)
    Medical condition: polymyalgia rheumatica
    Disease: Version SOC Term Classification Code Term Level
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10036099 Polymyalgia rheumatica PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002759-39 Sponsor Protocol Number: 20190194 Start Date*: 2021-04-01
    Sponsor Name:Amgen Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging, Phase 2b Study to Evaluate Efficacy and Safety of Tezepelumab for the Treatment of Chronic Spontaneous Urticaria
    Medical condition: Chronic Spontaneous Urticaria
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10072757 Chronic spontaneous urticaria PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) FR (Completed) IT (Completed) ES (Ongoing) PL (Completed)
    Trial results: View results
    EudraCT Number: 2018-001896-19 Sponsor Protocol Number: P2-IMU-838-MS Start Date*: 2018-12-17
    Sponsor Name:Immunic AG
    Full Title: Randomized, double-blind, placebo-controlled, multicenter Phase 2 trial assessing the effect of IMU-838 on disease activity, as measured by magnetic resonance imaging (MRI), as well as safety and t...
    Medical condition: relapsing-remitting multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BG (Trial now transitioned) DE (Trial now transitioned) RO (Trial now transitioned)
    Trial results: View results
    EudraCT Number: 2019-001793-28 Sponsor Protocol Number: 371b Start Date*: 2019-11-05
    Sponsor Name:Reade
    Full Title: Adalimumab dose reduction aiming low serum concentration with control of disease activity (ADDORA-LOW) : a single blind, non-inferiority, randomised clinical trial
    Medical condition: Rheumatoid arthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-004809-31 Sponsor Protocol Number: CAIN457R12301 Start Date*: 2021-09-24
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase III trial to investigate the efficacy and safety of secukinumab 300 mg administered subcutaneously versus placeb...
    Medical condition: giant cell arteritis
    Disease: Version SOC Term Classification Code Term Level
    23.1 10047065 - Vascular disorders 10018250 Giant cell arteritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) BE (Trial now transitioned) NO (Trial now transitioned) PT (Trial now transitioned) DE (Trial now transitioned) FI (Trial now transitioned) DK (Trial now transitioned) BG (Trial now transitioned) SE (Trial now transitioned) IT (Trial now transitioned) GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-003168-63 Sponsor Protocol Number: AMLSG16-10/CPKC412ADE02T Start Date*: 2012-04-27
    Sponsor Name:University Hospital Ulm
    Full Title: Phase-II study evaluating midostaurin in induction, consolidation and maintenance therapy also after allogeneic blood stem cell transplantation in patients with newly diagnosed acute myeloid leuk...
    Medical condition: Patients with confirmed diagnosis of AML or related precursor neoplasm, or acute leukemia of ambiguous lineage (classified according to the World Health Organization (WHO) 2008 classification)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2014-000998-39 Sponsor Protocol Number: TIDE-13-22 Start Date*: 2014-10-30
    Sponsor Name:Helsinn Healthcare SA
    Full Title: Randomized, double-blind, parallel group, placebo-controlled, dose finding study in colorectal cancer patients receiving 5-FU-based chemotherapy to assess the efficacy of different doses of s.c. el...
    Medical condition: Chemotherapy Induced Diarrhea (CID)
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004856 10056985 Diarrhoea post chemotherapy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) CZ (Prematurely Ended) BG (Completed)
    Trial results: View results
    EudraCT Number: 2019-003513-33 Sponsor Protocol Number: 21069 Start Date*: 2020-05-20
    Sponsor Name:Bayer HealthCare LLC
    Full Title: A Randomized, Double-Blind, Single-Dose, Parallel, Placebo-Controlled Trial to Determine the Dose of Caffeine in a Fixed Dose Combination Tablet of Naproxen Sodium and Caffeine to Effectively Allev...
    Medical condition: Pain, Postoperative
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004863 10054711 Postoperative pain LLT
    20.0 10042613 - Surgical and medical procedures 10061812 Dental operation PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2020-004032-21 Sponsor Protocol Number: ARGX-113-2004 Start Date*: 2021-05-07
    Sponsor Name:argenx BV
    Full Title: A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and the Safety of Efgartigimod (ARGX-113) PH20 Subcutaneous in Adult Patients With Primary Immu...
    Medical condition: Primary immune thrombocytopenia (ITP)
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004851 10083843 Primary immune thrombocytopenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) PT (Completed) DE (Completed) BG (Completed) NO (Completed) DK (Completed) GR (Completed) IT (Completed) FR (Completed) RO (Completed) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-004783-30 Sponsor Protocol Number: ARD12858-MOZ23510 Start Date*: 2013-01-21
    Sponsor Name:Sanofi aventis recherche et développement
    Full Title: A pilot, exploratory, randomized, phase 2 safety study evaluating tumor cell (plasma cell) mobilization and apheresis product contamination in plerixafor plus non-pegylated G-CSF mobilized patients...
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) LT (Completed) SE (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2017-004707-43 Sponsor Protocol Number: PP06489 Start Date*: 2018-08-09
    Sponsor Name:PledPharma AB
    Full Title: A Phase 3, double-blind, multicenter, placebo-controlled study of PledOx used on top of modified FOLFOX6 (5-FU/FA and Oxaliplatin) to prevent chemotherapy induced peripheral neuropathy (CIPN) in th...
    Medical condition: Chemotherapy induced peripheral neuropathy
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004852 10079545 Chemotherapy induced peripheral neuropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed) DE (Completed) GB (Completed) ES (Temporarily Halted) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jul 15 03:52:20 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA